Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Fair Value of Consideration Transferred

The up-front payment made and the fair value of the contingent payments payable by the Company pursuant to the Parion Agreement are set forth in the table below:

	June 4, 2015
	(in thousands)
Up-front payment	$	80,000
Fair value of contingent payments	175,340
Total	$	255,340

Schedule of Collaborative Arrangement Summary of Final Fair Values of the Assets and Liabilities Recorded on the Effective Date of the Agreement

:

	June 4, 2015
	(in thousands)
Consideration transferred	$	—
Noncontrolling interest	164,317
Intangible assets	(255,340		)
Net other liabilities	10,468
Deferred tax liability	91,023
Goodwill	$	10,468

Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest

An aggregate summary of net loss attributable to noncontrolling interest related to the Company’s VIEs for the three years ended December 31, 2016 was as follows:

	2016			2015			2014
	(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes	$	10,086		$	6,646		$	764
Provision for income taxes	16,743			29,731			3,876
Increase in fair value of contingent payments	(54,850		)	(4,530		)	(450		)
Net (income) loss attributable to noncontrolling interest	$	(28,021	)	$	31,847		$	4,190

Schedule of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities

The following table summarizes items related to the Company’s VIEs included in the Company’s consolidated balance sheets as of the dates set forth in the table:

	December 31, 2016		December 31, 2015
	(in thousands)
Restricted cash and cash equivalents (VIE)	$	47,762	$	78,910
Prepaid expenses and other current assets	6,812		3,138
Intangible assets	284,340		284,340
Goodwill	19,391		19,391
Other assets	399		455
Accounts payable	415		676
Taxes payable	1,330		24,554
Other current liabilities	2,137		7,100
Deferred tax liability, net	131,446		110,438
Other liabilities	300		300
Noncontrolling interest	181,609		153,661

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions - Royalty and Collaborative Revenues

During the three years ended December 31, 2016, the Company recognized the following revenues attributable to the Janssen HCV collaboration:

	2016			2015		2014
	(in thousands)
Royalty revenues	$	71		$	1,518	$	13,481
Collaborative revenues	$	(155	)	$	1,946	$	7,104
Total revenues attributable to the Janssen HCV collaboration	$	(84	)	$	3,464	$	20,585